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The developmental potential of human pluripotent
stem cells suggests that they can produce disease-
relevant cell types for biomedical research. However,
substantial variation has been reported among
pluripotent cell lines, which could affect their utility
and clinical safety. Such cell-line-specific differences
must be better understood before one can confi-
dently use embryonic stem (ES) or induced pluripo-
tent stem (iPS) cells in translational research. Toward
this goal we have established genome-wide refer-
ence maps of DNA methylation and gene expression
for 20 previously derived human ES lines and 12
human iPS cell lines, and we have measured the
in vitro differentiation propensity of these cell lines.
This resource enabled us to assess the epigenetic
and transcriptional similarity of ES and iPS cells
and to predict the differentiation efficiency of indi-
vidual cell lines. The combination of assays yields
a scorecard for quick and comprehensive character-
ization of pluripotent cell lines.
INTRODUCTION
Human embryonic stem (ES) cell lines can be cultured and
expanded for many passages in vitro, without losing their ability
to differentiate into all three embryonic germ layers (Thomson
et al., 1998). The same is true for induced pluripotent stem
(iPS) cell lines, which are obtained by reprogramming somatic
cells using ectopic expression of the transcription factors
OCT4, SOX2, KLF4, and C-MYC (Takahashi et al., 2007) or alter-
native reprogramming cocktails (reviewed in Stadtfeld andHochedlinger, 2010). Both ES and iPS cell lines are powerful
research tools and could provide substantial quantities of
disease-relevant cells for biomedical research. Several groups
have already used human pluripotent cell lines as a model
system for dissecting the cellular basis of monogenic diseases,
and the range of diseases under investigation is rapidly expand-
ing (reviewed in Colman and Dreesen, 2009). Future applications
of human pluripotent stem cell lines could include the study of
complex diseases that emerge from a mixture of genetic and
environmental effects; cell-based drug screening in disease-
relevant cell types; and the use of pluripotent cells as a renewable
source for transplantation medicine (Colman and Dreesen, 2009;
Daley, 2010; Rubin, 2008).
All of these applications require the selection and characteriza-
tion of cell lines that reliably, efficiently, and stably differentiate
into disease-relevant cell types. However, significant variation
has been observed for the differentiation efficiency of various
human ES cell lines (Di Giorgio et al., 2008; Osafune et al.,
2008), and further concerns have been raised about the equiva-
lence of human ES and iPS cell lines. For example, it has been
reported that human iPS cells collectively deviate from ES cells
in the expression of hundreds of genes (Chin et al., 2009), in their
genome-wide DNAmethylation patterns (Doi et al., 2009), and in
their neural differentiation properties (Hu et al., 2010). Suchdiffer-
ences must be better understood before human ES and iPS cell
lines can be confidently used for translational research. In partic-
ular, it is necessary to establish genome-wide referencemaps for
patterns of gene expression and DNA methylation in a large
collection of pluripotent cell lines, providing a baseline against
which comparisons of epigenetic and transcriptional properties
of new ES and iPS cell lines can be made. Previous research
has shown that human pluripotent cells exhibit highly character-
istic patterns of DNAmethylation and gene expression (Guenther
et al., 2010; Hawkins et al., 2010; Lister et al., 2009; Mu¨ller et al.,
2008). However, these studies focused on few cell lines andCell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc. 439
therefore could not systematically investigate the role of epige-
netic and transcriptional variation.
In order to firmly establish the nature and magnitude of epige-
netic variation that exists amonghumanpluripotent stemcell lines,
three genomic assays were applied to 20 established ES cell lines
(Chen et al., 2009; Cowan et al., 2004; Thomson et al., 1998) and
12 iPScell lines thatwere recentlyderivedand functionally charac-
terized (Boulting et al., 2011). The assays performed on each cell
line includedDNAmethylationmapping by genome-scale bisulfite
sequencing, gene expression profiling using microarrays, and
a novel quantitative differentiation assay that utilizes high-
throughput transcript counting of 500 lineage marker genes in
embryoid bodies (EBs). Collectively, our data provide a reference
of variation among human pluripotent cell lines. This reference
enabled us to perform a systematic comparison between ES and
iPS cell lines, to identify cell-line-specific outlier genes, and to
predict each cell line’s differentiation propensity into the three
germ layers. Finally, we show that the differentiation propensities
thatwe reportherearehighlypredictiveof theefficienciesbywhich
Boulting and colleagues could direct the differentiation of the
12 iPS cell lines into motor neurons (Boulting et al., 2011).
In summary, we found that epigenetic and transcriptional
variation is common among human pluripotent cell lines and
that this variation can have significant impact on a cell line’s
utility. Our observation applies to both ES and iPS cell lines,
underlining the need to carefully characterize each cell line,
regardless of how it was derived. As a step toward lowering
the experimental burden of comprehensive cell line characteriza-
tion and to improve the accuracy over existing assays, we have
combined our three genomic assays into a bioinformatic score-
card. This scorecard enables high-throughput prediction of the
quality and utility of any pluripotent cell line.
RESULTS
A Reference of DNA Methylation and Gene Expression
in Human ES Cell Lines
Human ES cell lines are subject to many factors of influence that
could contribute to epigenetic and transcriptional variation, such
as their genetic background, differences between derivation
protocols, and varying cell culture conditions. To establish
a baseline of variation among high-quality pluripotent cell lines,
we obtained low-passage freezes of 20 well-characterized and
widely used human ES cell lines (Table S1). These cell lines
were cultured for several passages under standardized condi-
tions, and we confirmed the expression of pluripotency markers
by immunostainings (Figure S1A) before collecting material for
genomic analysis of DNA methylation and gene expression.
DNA methylation profiling was performed by reduced-repre-
sentation bisulfite sequencing (RRBS) as described previously
(Gu et al., 2010; Meissner et al., 2008) and resulted in DNA
methylation measurements for approximately four million indi-
vidual CpG dinucleotides per cell line. The genomic coverage
was sufficient to determine DNA methylation levels for three
quarters of all gene promoters, the majority of CpG islands and
many other genomic elements (Figures S1B and S1C). Gene
expression profiling was performed using commercially avail-
able Affymetrix microarrays and gave rise to expression levels440 Cell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc.for a total of 15,210 Ensembl genes. All data are publicly avail-
able for visual browsing and download (http://scorecard.
computational-epigenetics.org/).
To determine whether the global patterns of DNA methylation
and gene expression would segregate ES cell lines into
subclasses, we performed hierarchical clustering (Figure 1A,
Table S2), which also included data from the 6 primary fibroblast
cell lines as nonpluripotent controls. Two well-separated
clusters emerged, one comprising all ES cell lines and the other
comprising all fibroblast cell lines. Within the ES cell cluster,
there was some indication that cell lines derived at the same
institution cluster together (HUES cell lines versus H1, H7,
and H9), which is consistent with a prior study of marker gene
expression in human ES cell lines (Adewumi et al., 2007).
However, this trend was mild compared to the difference
between pluripotent and nonpluripotent cells and did not signif-
icantly influence the results reported below.
Consistent with the overall similarity among all 20 ES cell lines,
the majority of genetic loci exhibit similar DNA methylation and
gene expression levels between different ES cell lines, as exem-
plified by the DNA methyltransferase gene DNMT3B (Figure 1B).
However, a moderate number of genes show variable DNA
methylation and/or gene expression levels. For example, the
antioxidant gene CAT exhibits substantial and correlated
variation of DNA methylation and gene expression; the develop-
mental regulator PAX6 exhibits gene expression variation and
a consistently unmethylated gene promoter; and the macro-
phage/granulocyte surface marker CD14 exhibits DNA methyla-
tion variation while not being expressed in any of the 20 ES cell
lines (Figure 1B). Importantly, cell-line-specific differences
were maintained when we collected biological replicates from
different passages of the same cell line (Figure S1D).
To investigate the variation observed among human ES cell
lines in a more quantitative manner, we calculated, for each
gene, the distribution of DNA methylation and gene expression
among the 20 ES cell lines (Table S3). The resulting ‘‘reference
corridor’’ quantifies the range of DNA methylation and gene
expression values for a given gene (or genomic region) in a refer-
ence set of pluripotent cell lines. Any measurement that falls
outside of this corridor is regarded as an outlier and could poten-
tially affect that cell line’s functional properties. We illustrate the
concept of the reference corridor using boxplots (Figure 1C),
which display the median and range of observed DNA methyla-
tion/expression levels for representative genes with different
degrees of variability. For each gene (or genomic region), these
plots impose upper and lower thresholds between which the
DNA methylation/expression levels must fall to be considered
‘‘within the range of the current ES cell reference.’’ With this
reference in hand, it becomes possible to determine the number
and identity of deviations in any pluripotent cell line by using
a statistical outlier filter (Tukey, 1977) and to investigate the
causes and potential consequences of this variation.
Causes and Consequences of Epigenetic and
Transcriptional Variation among Human ES Cell Lines
Plotting the deviation from the ES cell reference maps for all
genes confirmed our initial observation that epigenetic and tran-
scriptional variation focuses on a subset of genes, whereas most
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Figure 1. DNA Methylation and Gene Expression Profiles Quantify Variation among Human ES Cell Lines
(A) Joint hierarchical clustering of DNA methylation and gene expression in 20 human ES cell lines (‘‘HUESx,’’ ‘‘Hx’’) and 6 primary fibroblast cell lines (‘‘hFibx’’).
Light colors indicate high levels of DNA methylation (red) or gene expression (green), and dark colors indicate low levels. Joint DNA methylation and gene
expression data are available from Table S2.
(B) High-resolution view of DNA methylation and gene expression at four selected genes. DNA methylation patterns are shown for the promoter regions (5 kb
to +1 kb) of representative Ensembl-annotated transcripts. Each box on the left represents a single CpG dinucleotide (dark red: highmethylation, light red: little or
no methylation). The single boxes on the right visualize the normalized expression levels of each gene (dark green: little or no expression, light green: high
expression). The DNA methylation patterns are not drawn to scale.
(C) Boxplots of gene-specific DNA methylation (left) and gene expression levels (right) among 20 low-passage human ES cell lines, illustrating the concept of an
epigenetic/transcriptional reference corridor. Boxplot boxes correspond to center quartiles, themedian is marked by a black bar, and whiskers indicate the width
of the reference corridor as defined in the Extended Experimental Procedures (i.e., value of the most extreme data point that is no more than 1.5 times the
interquartile range from the box if the distance from the median exceeds a minimum threshold of 0.2 for DNA methylation and 1 for gene expression; otherwise
these thresholds—which correspond to 20 percentage points for DNAmethylation and a 2-fold change for gene expression—define the reference corridor). Data
points that fall outside the whiskers are flagged as outliers and are suppressed in this figure; their position relative to the reference corridor is shown in Figure 4A.genes exhibit little deviation from the reference in any of the ES
cell lines (Figure 2A). Specifically, 13% of genes account for
half of the total DNA methylation variation, and 20% of genes
account for half of the total gene expression variation
(Table S3). As one might have expected, housekeeping genes
such as GAPDH were among the least variable genes between
the cell lines. Similarly, we observed relatively low variationamong several genes that are highly expressed in pluripotent
cell lines, including SOX2 and DNMT3B. In contrast, moderate
to high levels of variation were found for several genes that regu-
late embryonic development and are induced upon ES cell differ-
entiation, including GATA6, LEFTY2, and PAX6. Finally, a small
number of loci exhibited highly variable DNA methylation levels
between cell lines, ranging from close to 0% methylation inCell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc. 441
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Figure 2. Epigenetic and Transcriptional Variation Targets Specific Genes and Influences Cellular Differentiation
(A) Distribution of cell-line-specific variation in terms of DNA methylation and gene expression. The histogram shows the number of genes (y axis) that fall into
each interval when calculating the mean absolute deviation of individual ES cell lines relative to the reference of all other ES cell lines (x axis). The position of
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some cell lines to almost 100% methylation in other cell lines.
The most prominent cases were CAT and CD14 (both shown in
Figure 1B) and the transferrin-encoding gene TF.
To gain insight into potential causes of the differences in vari-
ation, we bioinformatically compared the top 1000 most variable
genes with all other genes that were covered by our dataset. We
detected a striking enrichment of DNA methylation-variable
genes located on the sex chromosomes (Figure 2B), which is—
at least partially—due to the fact that we included both male
and female cell lines in our comparison. The measured levels
of Y-linked methylation and transcription vary between cell lines
because the Y chromosome is absent in female lines. Similarly,
DNAmethylationmeasurements vary between cell lines because
female ES cell lines often exhibit high levels of DNA methylation
on the inactivated X chromosome, which is not observed in male
cell lines (Lengner et al., 2010). As X-linked and Y-linked genes
were such a significant source of variation, we were concerned
that they might interfere with our ability to identify gene features
that more subtly influence transcriptional or epigenetic vari-
ability. We therefore excluded all loci that map to the sex chro-
mosomes from subsequent analyses.
We also found significant overlap between the sets of genes
that showed the greatest epigenetic and transcriptional
variability (Figure 2C). This observation suggests that DNAmeth-
ylation may play a regulatory role for a subset of the most tran-
scriptionally variable genes. Furthermore, bioinformatic analysis
identified significant enrichment of specific gene functions and
promoter patterns that characterize highly variable genes (Fig-
ure 2D). The most variably expressed genes were strongly en-
riched for Gene Ontology categories related to cellular signaling,
development, and the response to external stimuli. In contrast,
genes with variable DNA methylation levels showed little
evidence of enrichment for any particular function. Instead, we
found that the promoters of these genes shared common struc-
tural characteristics. Most notably, these promoters were rela-
tively depleted in CpG dinucleotides compared to the promoters
of nonvariable genes (most of which are CpG island promoters).
Comparatively low CpG frequency is a known characteristic of
genomic regions that are susceptible to variation in DNAmethyl-
ation (Bock et al., 2008; Keshet et al., 2006; Meissner et al.,selected genes within each histogram is highlighted on top. Note that the DNA m
axis has been compressed 5-fold for the right half of the diagram, which gives
histogram (right) is characterized by a strong peak at zero, due to a large number o
for all genes are available from Table S3.
(B) Chromosomal distribution of the 1000 most variable genes in terms of DNA
diagram also shows the chromosomal distribution of all genes with sufficient DN
(C) Comparison of the 1000 most variable genes in terms of DNA methylation
differences of male versus female cell lines, all X-linked and Y-linked genes were
(D) Functional and structural characteristics of the 1000 most variable genes in ter
clustering was performed with the DAVID software (Huang et al., 2007), and the
et al., 2009). This panel provides a summary of the results; the full results tables
(E) Epigenetic and transcriptional differences between two ES cell lines (HUES6 a
methylation levels were measured by clonal bisulfite sequencing at day 0 and da
CpGs, and black beads correspond tomethylated CpGs. Rows correspond to ind
of CD14. Similarly, gene expression of CD14 and two additional macrophage m
experiments (shown are three technical replicates) at day 0 and day 18 of the di
(F) Cell-line-specific DNAmethylation and gene expression levels at four genes wi
CAT). Each data point denotes the combined DNA methylation (x axis) and gene
embryoid body (‘‘EB’’).2008). These observations suggest that variation among ES
cell lines is not random but follows certain biological principles.
To test whether epigenetic variation has consequences for ES
cell function, we compared the differentiation potential of ES cell
lines that differed in the DNAmethylation level at theCD14 locus,
which stood out as one of the most epigenetically variable genes
in our dataset (Figure 2A). CD14 encodes a well-characterized
macrophage/granulocyte surface marker and is functionally
important for the innate immune response to bacterial lipopoly-
saccharide (Kitchens, 2000). Epigenetic defects at this locus
could therefore compromise the ability of ES cell lines to differen-
tiate into CD14-positive macrophages. We selected two ES cell
lines that differed in their DNA methylation at the CD14 locus
(HUES6: partial methylation, HUES8: complete methylation)
and performed directed differentiation toward the hematopoietic
lineage (Figure 2E).We found that HUES6was able to upregulate
CD14 expression, whereas the CD14 locus remained fully
methylated and silent during hematopoietic differentiation of
the HUES8 cell line. Two additional macrophage marker genes
(CD33 and CD64) were also more highly expressed in hemato-
poietic cells derived from HUES6 compared to HUES8, indi-
cating that the latter cell line is compromised in its ability to
produce macrophage-like cells in vitro.
To identify further examples of cell-line-specific DNAmethyla-
tion defects that might interfere with differentiation, we
compared the DNA methylation and gene expression levels of
five ES cell lines with their corresponding day 16 EBs (Figure 2F).
Among the most interesting cases were two additional genes
with a known role in hematopoietic cells: the alpha-globin tran-
scription factor TFCP2 is hypermethylated and lowly expressed
in the H1 ES cell line, indicating that this cell line may be less
suitable for studying erythrocyte differentiation; and the lympho-
cyte antigene LY6H is hypermethylated and silenced specifically
in the HUES3 cell line. We also found that the widely varying DNA
methylation and gene expression levels of CAT (Figure 1B) were
maintained during EB differentiation (Figure 2F). Given the
central role of CAT in the response to oxidative stress, these
differences could be relevant for a wide range of cell types
including hematopoietic and neural cells. COMT is another
example with potential relevance for neural cells. It isethylation histogram (left) is extremely skewed; for better representation the x
rise to an artificial peak in the center of the histogram. The gene expression
f genes with zero expression and zero variation in all ES cell lines. Variation data
methylation (top left) and gene expression (bottom left). For comparison, the
A methylation (top right) or gene expression data (bottom right).
(left) and gene expression (right). To prevent bias due to the chromosomal
excluded. Significance of overlap was confirmed by Fisher’s exact test.
ms of DNAmethylation (left) and gene expression (right). Functional annotation
promoter characteristics were analyzed by the EpiGRAPH web service (Bock
are available online http://scorecard.computational-epigenetics.org/.
nd HUES8) subjected to a defined hematopoietic differentiation protocol. DNA
y 18 of the differentiation protocol. White beads correspond to unmethylated
ividual clones, and columns correspond to specific CpGs in the promoter region
arker genes (CD33 and CD64) was measured by qPCR in two independent
fferentiation protocol. Error bars indicate ± one standard deviation.
th a known role in hematopoiesis (TFCP2, LY6H) and neural processes (COMT,
expression (y axis) levels of an ES cell lines (‘‘ES’’) or the corresponding 16 day
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hypermethylated and downregulated in HUES6 and H1, sug-
gesting that these two cell lines may produce neural cells that
are defective in their ability to inactivate neurotransmitters, which
is an important function of the COMT gene. All of these cases
highlight the relevance of monitoring DNA methylation and
gene expression to prospectively identify cell-line-specific
defects that could interfere with their differentiation or the func-
tional properties of derived cell types.
Comparison of DNA Methylation and Gene Expression
Variation between Human ES and iPS Cell Lines
The reference maps of variation among ES cell lines enabled us
to systematically address the contentious issue of epigenetic
and transcriptional differences between human ES and iPS cell
lines (Chin et al., 2009, 2010; Doi et al., 2009; Guenther et al.,
2010; Newman and Cooper, 2010). Four technical aspects
distinguish our comparison from previous studies: (1) we
compare both DNA methylation and gene expression in the
same cell lines; (2) we use a relatively large sample size of 20
ES and 12 iPS cell lines; (3) all cell lines were maintained under
the same standardized culture conditions; (4) we compare
each ES or iPS cell line individually against the ES cell reference,
rather than comparing the set of all ES cell lines against the set of
all iPS cell lines (this approach increases the robustness toward
a small number of strong outliers that could easily skew a group-
wise comparison).
The iPS cell lines were derived by Boulting and colleagues
using retroviral transduction of OCT4, SOX2, and KLF4 of fibro-
blasts obtained from six unrelated donors. This ‘‘test set’’ of 12
well-characterized human iPS cell lines is available as an inde-
pendent resource via the Harvard Stem Cell Institute’s iPS Cell
Core Facility (Boulting et al., 2011). To match the passage
numbers of the 20 ES cell lines and to avoid increased noise in
extremely low-passage iPS cell lines (Chin et al., 2009; Polo
et al., 2010), we focused our analysis on iPS cells in the range
of passage 15 to passage 30 (Table S1). DNA methylation and
gene expression profiling were performed on these iPS cell lines
in the same way as for the ES cell lines.
Hierarchical clustering confirmed that all iPS cell lines grouped
with the ES cell lines, rather than with the fibroblasts (Figure 3A
and Figure S2A). No clear-cut separation between ES and iPS
cell lines was observed, indicating that their global DNA methyl-
ation and gene expression profiles are highly similar. However,
hierarchical clustering has known limitations (Allison et al.,
2006), which may prevent it from picking up subtle differences
between these ES and iPS cell lines.
For a more quantitative comparison, we calculated—for each
cell line—the mean deviation from the ES cell reference over all
genes (Figure 3B). The results indicate that many iPS cell lines
fall well within the range of global deviation that is also observed
among ES cell lines, although the average deviation is somewhat
higher among the iPS cell lines compared to the ES cell lines. We
also investigated whether there are any specific marker genes
that reproducibly distinguish ES and iPS cell lines. To that end,
we calculated—for each gene—the mean deviation from the
ES cell reference separately in all ES and iPS cell lines and
plotted these gene-specific deviations against each other
(Figure 3C). The vast majority of genes exhibit similar deviation444 Cell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc.averages in ES cell lines and in iPS cell lines. This is true for
highly variable genes (e.g., CAT) as well as for genes that exhibit
little variation (e.g., GAPDH). This global concordance is also
reflected in high correlation between deviation in ES and iPS
cell lines (Pearson’s r = 0.87). However, for a small number of
genes we observed substantially increased deviation from the
ES cell reference among the iPS cell lines (Figure 3C). Some of
these genes were hypermethylated in a subset of iPS lines, for
example the protease HTRA4 (9 out of 12 iPS cell lines) and
the relaxin hormones RLN1/2 (9 out of 12 iPS cell lines; although
also hypermethylated in one ES cell line). Others were
transcribed at higher levels in some iPS cell lines, such as the
transcription factor EGR4 (6 out of 12 iPS cell lines) and the
matrix Gla protein MGP (3 out of 12 iPS cell lines).
The HTRA4 gene, which is most frequently hypermethylated in
iPS cell lines compared to ES cell lines (9 out of 12 iPS versus
0 out of 20 ES cell lines), is also hypermethylated in all six fibro-
blast cell lines. This observation suggests that somatic cell
memory (i.e., incomplete reprogramming of DNA methylation
at genes that are methylated in fibroblasts) might provide
a potential explanation for the deviation in some iPS cell lines.
To address this point in a quantitative way, we built a statistical
model that estimates the relative contribution of epigenetic
memory to the DNAmethylation levels observed in iPS cell lines.
Specifically, we asked how much better we can predict each
gene’s average DNA methylation in iPS cell lines if we know its
DNA methylation state in both fibroblasts and ES cells,
compared to knowing only its DNA methylation state in ES cells.
This question can be addressed by comparing the predictive
power of linear models that implement both explanations. The
results were highly conclusive: including the DNA methylation
in fibroblasts led to a significantly more accurate model
(p < 108), but the increase in accuracy was extremely low
(Dr2 < 105). Similar results were also obtained for somatic
memory of gene expression (p < 108, Dr2z104), indicating
that somatic memory cannot explain more than a very small
fraction (0.01% to 0.001%) of the DNA methylation and gene
expression observed in human iPS cell lines.
PerformanceEvaluation of Classifiers forDistinguishing
between ES and iPS Cell Lines
The analysis described above identified small but significant
differences between the ES cell lines and iPS cell lines. Two
alternative models could explain these observations. On the
one hand, these differences could systematically affect all iPS
cell lines; on the other hand, they could be specific to a subset
of ‘‘deviant’’ iPS cell lines. To quantitatively address this issue,
we reframed them as a classification problem: Can we use
DNA methylation and gene expression profiles to accurately
predict whether a specific cell line is an ES or iPS cell line?
Several gene signatures of differences between human ES
and iPS cell lines have been reported in the literature (Chin
et al., 2009; Doi et al., 2009; Stadtfeld et al., 2010). We started
our prediction efforts by evaluating the predictive power of three
published signatures on the current sample set. (1) The iPS-
specific transcription signature reported by Chin et al. exhibits
significant overlap with the set of genes that are more highly
expressed in iPS than in ES cell lines in the current study (odds
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Figure 3. Cell-Line-Specific Deviation from the Reference Is Slightly Higher in iPS than in ES Cell Lines
(A) Joint hierarchical clustering of 12 iPS cell lines (‘‘hiPSx’’), 20 ES cell lines (‘‘HUESx,’’ ‘‘Hx’’), and 6 primary fibroblast cell lines (‘‘hFibx’’). An extended version
that includes heatmaps is available from Figure S2A. The numbers of the iPS cell lines connect them to the fibroblasts fromwhich they were derived (e.g., hFib 18
was used to generate hiPS 18a, 18b, and 18c).
(B) Boxplots of the cell-line-specific deviation from the ES cell reference, averaged over all genes and scaled such that the mean deviation of the 20 ES cell lines is
equal to 100%.
(C) Scatterplots comparing the gene-specific deviation of 20 ES cell lines (x axis) with the gene-specific deviation of 12 iPS cell lines (y axis), in both cases
measured relative to the ES cell reference and averaged over all ES or iPS cell lines, respectively. To prevent comparing cell lines to themselves, each ES cell line
was temporarily removed from the ES cell reference when it was compared to the reference. Selected genes are highlighted in orange, rp refers to Pearson’s
correlation coefficient, and the inset Venn diagrams visualize the overlap between the 2000 most deviating genes in ES versus iPS cell lines. The reprogramming
factors OCT4, SOX2, and KLF4 were excluded from the DNA methylation analysis because transgene silencing gives rise to spurious hypermethylation among
the iPS cell lines (Figure 4A and Figure S2C).
(D) Performance table summarizing the predictive power of three previously published iPS cell signatures and three newly derived classifiers for distinguishing
between ES and iPS cell lines. For comparison, the table also lists the performance of three newly derived classifiers for distinguishing between ES cell lines and
fibroblasts (positive controls) and the performance of three trivial classifiers (negative controls). Shown are the prediction accuracy, sensitivity, and specificity for
identifying iPS cell lines (true positives, TP) among ES cell lines (true negatives, TN), while minimizing the number of cell lines that are incorrectly predicted as iPS
cell lines (false positives, FP) or incorrectly predicted as ES cell lines (false negatives, FN). To increase the robustness of the results, all values were averaged over
100 randomized repetitions of the cross-validation. Minor numerical inconsistencies in the table are due to rounding all values to whole numbers.ratio = 1.54, p = 0.01, Table S4). However, the overlap is low in
absolute terms and insufficient for correctly identifying individual
iPS cell lines (Figure 3D). (2) The iPS-specific DNA methylation
signature reported by Doi et al. also shows a trend toward being
consistent with the current sample set (odds ratio = 1.58,
p = 0.73, Table S4), but this trend was not significant and also
insufficient for correctly identifying individual iPS cell lines (Fig-
ure 3D). Importantly, a much higher concordance was observed
for the fibroblast-specific DNA methylation signature from thesame study (odds ratio = 152.03, p < 1015, Table S4), suggest-
ing that the low concordance for the iPS-specific DNA methyla-
tion signature cannot be explained by the different DNA methyl-
ation assays used. (3) The Gtl2/MEG3 single-gene signature that
was reported by Stadtfeld et al. in mouse exhibited 100% sensi-
tivity but only moderate specificity in our sample set (Figure 3D).
Almost half of the ES cell lines were MEG3 negative and thus
incorrectly classified as iPS cell lines (Figure S2A). It is not
possible to test whether absence of MEG3 expression has theCell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc. 445
same consequences as reported in mouse, namely to interfere
with normal development in the tetraploid embryo complemen-
tation assay (Stadtfeld et al., 2010). However, we found no
evidence that would speak against using MEG3-negative ES or
iPS cell lines in biomedical research. Specifically, MEG3-nega-
tive ES cell lines exhibit similar levels of variation in DNA methyl-
ation and gene expression as did MEG3-positive ES cell lines
(Figure S2B), and several MEG3-negative ES cell lines have
been widely and productively used for in vitro studies.
Finally, we tested whether we could use the current dataset to
develop amore accurate classifier for distinguishing between ES
and iPS cell lines. Tominimize the risk of overfitting to the training
data, or overestimating the prediction accuracy of our classifier,
we employed a stringent statistical learning approach (Hastie
et al., 2001). Specifically, we abstained from any manual param-
eter optimization or feature selection (which are notorious for
inflating accuracies when used incorrectly), and we assessed
the performance of the trained classifiers only on test cases
that were not included in the training dataset. The best classi-
fier—a support vector machine trained on DNA methylation
and gene expression data—achieved an overall accuracy of
81%, which outperformed all three previously reported iPS
gene signatures. The classifier’s specificity was high (91%),
indicating that few ES cell lines were incorrectly predicted to
be iPS cell lines. However, it achieved only moderate sensitivity
(64%), hence there were more iPS cell lines predicted to be ES
cell lines than vice versa. In summary, these results indicate
that most, but not all, iPS cell lines exhibit characteristic DNA
methylation and/or gene expression profiles by which they can
be distinguished from ES cell lines.
A Scorecard for Evaluating the Quality and Utility
of Human Pluripotent Cell Lines
It has become clear from our analysis so far that human pluripo-
tent cell lines vary in their DNA methylation and gene expression
(Figure 1), which can have functional implications (Figure 2) and
affects both ES and iPS cell lines (Figure 3). These results
indicate that all ES and iPS cell lines should be carefully moni-
tored for DNA methylation or gene expression alterations that
could interfere with an intended application or confound biolog-
ical interpretations. To provide an informative and practically
useful method for high-throughput cell-line characterization,
we bioinformatically integrated several genomic assays into
a scorecard that measures the quality and utility of any human
pluripotent cell line.
In a first step, we compared the DNA methylation and gene
expression profiles of the 12 iPS cell lines with the ES cell refer-
ence, in order to identify iPS cell lines with epigenetic or
transcriptional defects that might interfere with motor neuron
differentiation. The hierarchical clustering already yields important
information (Figure 3A): All 12 iPS cell lines globally cluster with the
ES cell lines, confirming that no partially reprogrammed or grossly
abnormal cell lines were included in our study. Next, we tested for
each gene whether or not its DNA methylation and gene expres-
sion levels fall within the range observed among ES cell lines (Fig-
ure 4A). Genes outside of this rangewere flagged, and the number
and identity of these outlier genes were tracked for each iPS cell
line. The results of the outlier detection were summarized as446 Cell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc.a ‘‘deviation scorecard’’ (Figure 4B). It is apparent from this score-
card that individual iPS cell lines can harbor several hundred
outlier genes. Importantly, this was also true for the ES cell lines
we studied, and it is likely that not all outliers will have detectable
functional consequences. We manually inspected the extended
version of the deviation scorecard (Table S5), searching for known
genes that might specifically interfere with neural differentiation or
motor neuron function. One cell line (hiPS 17a) was flagged
because it exhibits significantly increased DNA methylation at
the glutamate receptor gene GRM1, a gene that is important for
motor neuron function and survival (Nistri et al., 2006). In contrast,
if we were studying pancreatic differentiation rather than motor
neuron function, we might have kept hiPS 17a but avoided hiPS
27b due to hypermethylation at the pancreatic transcription factor
PAX4.
In summary, DNAmethylation and gene expression profiling in
combination with bioinformatic comparison to an ES cell refer-
ence provide a quick and comprehensive method for excluding
cell lines that could be problematic for an intended application.
However, there may be other characteristics of a cell line that
we cannot readily predict from epigenetic and transcriptional
profiles, for example its specific genetic background or the
presence of acquired mutations in key developmental genes.
To overcome these limitations, we sought to complement the
‘‘deviation scorecard’’ with a ‘‘lineage scorecard’’ that directly
reflects a cell line’s in vitro differentiation potential. To be practi-
cally useful, such a lineage scorecard cannot rely on expensive
and time-consuming directed differentiation protocols. Instead
we chose a simple nondirected EB differentiation assay and
combined it with highly quantitative gene expression profiling
and a bioinformatic algorithm that quantifies a cell line’s differen-
tiation propensity for multiple lineages. The experimental and
bioinformatic protocol of this quantitative differentiation assay
is outlined in Figure 5A and described in more detail in Figure S4
and in the Extended Experimental Procedures.
To test and calibrate the lineage scorecard for pluripotent
cells, we initially applied it to our reference set of 20 ES cell lines.
Embryoid bodies were obtained in biological duplicate for each
ES cell line, RNA was collected and profiled for the expression
levels of 500 marker genes, and the cell-line-specific differentia-
tion propensities were estimated for each of the three germ
layers as well as for the neural and hematopoietic lineages (Fig-
ure 5B, Table S6). The resulting lineage scorecard pinpoints
quantitative differences among the cell-line-specific differentia-
tion propensities. For example, HUES8 showed the greatest
propensity for endoderm differentiation, corroborating previous
results showing that this cell line performs well in directed
endoderm differentiation (Osafune et al., 2008). This result may
also explain why HUES8 is frequently used for directed endo-
derm differentiation (Borowiak et al., 2009). In contrast, H1 and
H9 received high scores for neural lineage differentiation (Fig-
ure 5B), suggesting that they might be an excellent choice for
applications in the study or treatment of neural degeneration.
These cell lines indeed performed well in a recent report of
directed differentiation into motor neurons (Hu et al., 2010).
We performed several additional validations of the lineage
scorecard, in order to establish its utility for quantifying cell-
line-specific differentiation propensities. First, we compared
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Figure 4. Comparison with the Reference Corridor Identifies Cell-Line-Specific Outlier Genes
(A) Distribution of gene-specific DNA methylation (left) and gene expression levels (right) among 20 ES cell lines and 12 iPS cell lines, plotted against the ES cell
reference corridor (cf. Figure 1C). ES or iPS cell lines that fall outside of the corridor are highlighted by colored triangles.
(B) Deviation scorecard summarizing the cell-line-specific number of outliers relative to the ES cell reference, in terms of DNA methylation (left) and gene
expression (right). As an additional indication of a cell line’s quality, the scorecard lists the number of affected lineage marker genes. The table also shows the
mean number of deviating genes in the 20 low-passage ES cell lines (bottom row), providing an indication of what numbers arewithin a range that is also observed
among low-passage ES cell lines. A more comprehensive version of this scorecard is available from Table S5.the differentiation propensities determined by the lineage score-
cardwith the expression levels of fivewidely used lineagemarker
genes (NES, TUBB3, KDR, ACTA2, AFP) and found good quali-
tative agreement (Figure S3A). Second, we subjected four ES
cell lines to two differentiation protocols that were biasing cells
toward ectoderm and mesoderm, respectively. Cell lines that
were cultured in the presence of Noggin and an ALK inhibitor
(SB431542) to promote ectoderm differentiation exhibited
substantially increased ectoderm scores and lower mesoderm
scores, compared to cell lines that were cultured in the presence
of Activin A andBMP4 to promotemesoderm differentiation (Fig-
ure S3B). These validation data suggested that the lineage
scorecard accurately detects differences in the differentiation
propensity of human pluripotent cell lines.
We next performed nondirected differentiation of 14 iPS cell
lines into EBs and profiled the expression levels of the 500
marker genes after 16 days of EB differentiation. To globally
assess the similarity between ES cell- and iPS cell-derived
EBs, we calculated a two-dimensional similarity map of all bio-
logical replicates (Figure 5C). The results were consistent with
Figure 3, indicating that most, but not all, EBs can be identifiedas ES cell or iPS cell derived. Furthermore, the scorecard
predicted that three iPS cell lines had an impaired ability to differ-
entiate (hiPS 15b, hiPS 27e, and hiPS 29e), whichmight limit their
usefulness for many applications. Indeed, the lineage scorecard
indicates that the neural differentiation propensity of hiPS 27e
and hiPS 29e is very low, whereas the predicted neural differen-
tiation propensity of hiPS 15b is only marginally reduced relative
to an average human ES cell line (Figure 5D). This prediction is
consistent with observations by Boulting and colleagues, who
showed that lines 27e and 29e are impaired in motor neuron-
directed differentiation, whereas line 15b differentiated relatively
well (Boulting et al., 2011). In addition, line 27e seemed to be
impaired in its ability to differentiate into any germ layer. To
confirm this prediction for an additional germ layer, we per-
formed flow cytometry to analyze the percentage of cells that
expressed the endodermal marker gene AFP in dissociated
EBs (Figure S3C). The percentage was substantially lower in
hiPS 27e as compared to hiPS 17a (which we used as a control),
providing further confirmation of the lineage scorecard’s ability
to detect cell-line-specific differences in the differentiation
propensities.Cell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc. 447
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Figure 5. A Quantitative Differentiation Assay Measures Cell-Line-Specific Differentiation Propensities
(A) Outline of the lineage scorecard assay for quantifying cell-line-specific differentiation propensities using a combination of nondirected EB differentiation,
highly quantitative expression profiling, and bioinformatic analysis of lineage marker gene enrichment.
(B) Lineage scorecard summarizing cell-line-specific differentiation propensities of a set of low-passage human ES cell lines. The numbers indicate relative
enrichment (positive values) or depletion (negative values) of lineage marker expression in the EBs derived from each cell line. An ES cell line will exhibit
a differentiation propensity of zero if it differentiates just like the average of all other ES cell lines that were used to calibrate the assay. Values should be interpreted
relative to each other, with higher numbers indicating higher differentiation propensities and lower values indicating lower differentiation propensities, while the
absolute values have no measurement unit and no direct biological interpretation. Gene lists, expression values, and gene-specific enrichment values are
available from Table S6.
(C) Multidimensional scaling map of the transcriptional similarity between ES and iPS cell lines, ES-derived and iPS-derived EBs, and primary fibroblast cell lines.
Each point corresponds to a single biological replicate. Cell lines that were impaired or unable to form normal EBs are highlighted by arrows.
(D) Lineage scorecard summarizing cell-line-specific differentiation propensities of a set of human iPS cell lines. The scorecard was derived in the same way as
Figure 5B, and all values were normalized relative to the ES cell reference. The scores were calculated across all biological replicates that were available for each
cell line. Further details on single biological replicates and the reproducibility of the lineage scorecard are available from Table S6G.Based on the results of the lineage scorecard, hiPS 18b, hiPS
18c, and hiPS 27b appear to be well-suited for studying neural
function in vitro, as these cell lines obtained high scores for ecto-
derm and neural differentiation propensity. Independent results
obtained in the study by Boulting et al. provide an opportunity to
quantitatively test these predictions. They used the test set of
iPS cell lines, applied a 32 daymotor neuron-directed differentia-
tion protocol (Di Giorgio et al., 2008), and then quantified the effi-
ciency with which each cell line could be differentiated into motor448 Cell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc.neurons.Whenwecompared the scorecardpredictions for neural
differentiation for each iPS cell line with the actual motor neuron
differentiation efficiency they observed (Figure 6, Table S7), we
found a remarkably high correlation (Pearson’s r = 0.87). Notably,
the three iPS cell lines that were predicted to behave optimally by
our scorecard (hiPS 18b, hiPS 18c, and hiPS 27b) were all among
the cell lines they found to differentiate best into motor neurons.
The high correlation between the lineage scorecard predictions
and the experimentally determined differentiation efficiencies
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Figure 6. The Lineage Scorecard Predicts
Cell-Line-Specific Differences in the Effi-
ciency of Motor Neuron Differentiation
Correlation between the lineage scorecard esti-
mates for the neural lineage and three germ layers
versus the cell-line-specific efficiency of directed
differentiation into motor neurons (rp, Pearson’s
correlation coefficient; rs, Spearman’s correlation
coefficient). Motor neuron efficiencies were
measured by the percentage of ISL1-positive cells
at the end point of a 32 day neural differentiation
protocol. Further details including biological
replicates and standard errors are available from
Table S7.was specific for the ectoderm germ layer and did not extend to
mesoderm or endoderm (Figure 6). This final observation shows
that the scorecard can detect lineage-specific differences in the
differentiation propensities of a given cell line, rather than merely
measuring the overall recalcitrance or amenability of a cell line
toward differentiation into any sort of cell.
In summary, we have described how a ‘‘deviation scorecard’’
derived from genome-wide maps of DNA methylation and gene
expression can have utility for predicting which iPS cell lines
should be avoided for a given application. In addition, we devel-
oped a ‘‘lineage scorecard’’ that combines simple nondirected
differentiation with RNA counting, which could predict the
efficiency with which iPS cell lines made motor neurons in an
independent study (Boulting et al., 2011). Together, these score-
cards enabled us to predict the quality and utility of more than
30 pluripotent cell lines for a broad range of applications.
DISCUSSION
To better understand the causes and consequences of variation
among human pluripotent cell lines, we used genomic methods
to characterize a panel of 20 ES cell lines and 12 iPS cell lines.
All cell lines exhibited similar DNA methylation and gene expres-
sion levels, which clearly denoted them as pluripotent and set
them apart from somatic cells. Despite their global similarity,
we could identify in each cell line a number of genes that devi-
ated from the DNA methylation or gene expression levels of
the other cell lines. These cell-line-specific outliers were rela-
tively stable over time, and our dataset suggests that someCell 144, 439–452may have functional consequences, for
example by interfering with differentiation
into certain cell types. Cell-line-specific
outliers were slightly more prevalent
among iPS cell lines than among ES cell
lines, but we could not find any epigenetic
or transcriptional deviation that was
unique to and shared by all iPS cell lines.
This observation was confirmed by
developing bioinformatic classifiers,
which could correctly identify most but
not all iPS cell lines in our dataset based
on their DNA methylation and gene
expression profiles.These results suggest that ES and iPS cells should not be
regarded as one or two well-defined points in the cellular space
but rather as two partially overlapping point clouds with inherent
variability among both ES and iPS cell lines (Figure 7A). In this
model, a single iPS cell line can be indistinguishable from ES
cell lines, even though there is a difference in our current dataset
between the average ES cell line and the average iPS cell line
(denoted by the two crosses in Figure 7A).
These observations have important practical implications. On
the one hand, equivalence to ES cell lines is unlikely to be
a sufficient indicator of an iPS cell line’s utility for a specific appli-
cation, given that cell-line-specific outliers were prevalent even
among ES cell lines. On the other hand, no single cell line may
be equally powerful for deriving all cell types in vitro, implying
that researchers would benefit from identifying the best cell lines
specifically for each application. Unfortunately, the teratoma
assay (Daley et al., 2009) does not provide the level of specificity
and detail that would support application-specific selection of
the most suitable cell lines (cf. Boulting et al., 2011). Teratomas
are also too time consuming and expensive to be feasible for
validating a large cohort of iPS cell lines, highlighting the demand
formore informative and efficient assays that can be used to vali-
date human pluripotent cell lines.
We sought to address the need for better validation assays by
developing a genomic scorecard of pluripotent cell line quality
and utility. The cell-line-specific outliers detected by DNA meth-
ylation and gene expression profiling were aggregated into
a deviation scorecard (Figure 4 and Table S5), which enables
researchers to quickly identify defects at known genes that are, February 4, 2011 ª2011 Elsevier Inc. 449
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Figure 7. The Scorecard Enables Quick and
Comprehensive Characterization of Human Plurip-
otent Cell Lines
(A) Schematic illustration of the similarity between ES and
iPS cell lines in the epigenetic and transcriptional space.
The density plot on the left depicts the variation observed
among human ES cells. The two crosses indicate the
(hypothetical) average of all ES and iPS cell lines, which
this study approximated by profiling 20 human ES cell lines
and 12 human iPS cell lines. The scatterplot on the right
simulates the distribution of a large number of human iPS
cell lines, taking into account their moderately increased
variation (Figure 3B) as well as the observation that
a minority of iPS cell lines were indistinguishable from ES
cell lines (Figure 3D). Gaussians were used to simulate the
ES cell and iPS cell distribution in silico.
(B) Outline of a workflow for high-throughput character-
ization of human pluripotent cell lines. Cell line character-
ization is performed in an iterative fashion, starting with the
quantitative differentiation assay andperformingadditional
characterizations only on those cell lines that the lineage
scorecard identifies as useful for the application of interest.relevant for the intended application. This gene-specific view
was complemented by the lineage scorecard, which provides
a systems-level assay for quantifying how well each cell line
can be differentiated into the neural and hematopoietic lineages,
and into the three germ layers (Figures 5B and 5D).We tested the
practical utility of this scorecard by comparing its results with
independently derived motor neuron differentiation efficiencies
and showed that it was highly predictive (Boulting et al., 2011).
Because the scorecard does not involve any labor-intensive
steps, it becomes feasible to quickly screen through a large
number of iPS cell lines in order to find the most appropriate
cell lines for an intended application (Figure 7B). Furthermore,
the scorecard provides a substantially more detailed character-
ization than for example the teratoma assay, and it therefore
seems plausible that genomic scorecards could over time super-
sede the teratoma assay as the gold standard for validating
human pluripotent cell lines. To assist researchers who want to
use the scorecard on their own cell lines, we provide an extended
technical note in the Extended Experimental Procedures. The450 Cell 144, 439–452, February 4, 2011 ª2011 Elsevier Inc.scorecard can readily be adapted to other proto-
cols for DNA methylation and gene expression
profiling, and it is easy to incorporate new cell
types in the prediction of the lineage scorecard.
In the future, it will be necessary to validate the
predictiveness for additional directed differenti-
ation protocols, and it may occasionally be
necessary to recalibrate the scorecard (e.g., for
directed differentiation protocols that do not
involve an EB step). The scorecard could also
provide a useful readout when optimizing cell
culture conditions, developing new reprogram-
ming protocols, or continuously monitoring cell
line quality in large-scale production facilities.
For example, it will be interesting to measure
whether the use of integration-free methods forreprogramming (Soldner et al., 2009; Warren et al., 2010) has
an effect on the differentiation propensities of iPS cell lines.
In conclusion, the discovery of human pluripotent cells and the
reprogramming methods to produce them from selected patient
populations has revolutionized the way we think about studying
and treating human disease. However, if we are to efficiently and
effectively use these discoveries to improve the lives of patients,
we must continue to develop tools (such as the scorecard
described herein) that optimize and streamline the selection
and monitoring of pluripotent cell lines and their differentiating
progeny.EXPERIMENTAL PROCEDURES
Cells Lines
A total of 20 human ES cell lines, 14 human iPS cell lines, and 6 primary fibro-
blast cell lines were included in the study (Table S1). The ES cell lines were ob-
tained from the Human Embryonic Stem Cell Facility of the Harvard Stem Cell
Institute (17 ES cell lines) and from the WiCell Research Institute’s WISC Bank
(3 ES cell lines). The iPS cell lines were derived by retroviral transduction of
OCT4, SOX2, and KLF4 in dermal fibroblasts (Boulting et al., 2011). All plurip-
otent cell lines have been characterized by conventional methods (Chen et al.,
2009; Cowan et al., 2004) and were grown under standardized conditions as
described in the Extended Experimental Procedures.DNA Methylation Mapping
RRBS was performed according to a previously published protocol (Smith
et al., 2009) with some optimizations for small cell numbers (Gu et al., 2010).
Using Maq’s bisulfite alignment mode (Li et al., 2008), the raw sequencing
reads were aligned to a human genome sequence that had been MspI-di-
gested and size-selected in silico. DNA methylation calling was performed
using custom software (Gu et al., 2010). Next, we calculated mean DNAmeth-
ylation levels for all gene promoters that were covered by a minimal number of
DNA methylation measurements (Bock et al., 2010). Gene promoters were
defined as the 5 kb to +1 kb sequence window surrounding the annotated
transcription start site of Ensembl-annoted genes (Hubbard et al., 2009).
Data processing was performed by custom Python (http://python.org/) and
R (http://www.r-project.org/) scripts.Gene Expression Profiling
Microarray analysis was performed by the microarray core facility at the Broad
Institute. Affymetrix GeneChip HT HG-U133A microarrays were used
throughout. The microarray intensity data were normalized using Bioconduc-
tor’s gcRMA package (Gentleman et al., 2004) and quality-controlled using
arrayQualityMetrics (Kauffmann et al., 2009). Data analysis was performed
with the R statistics package (http://www.r-project.org/).Quantitative Embryoid Body Assay
EB differentiation was performed as described in the Extended Experimental
Procedures. On day 16, cells were lysed and total RNA was extracted using
Trizol (Invitrogen), followed by column clean-up using the RNeasy kit
(QIAGEN). Subsequently, 300 ng to 500 ng of RNA was profiled on the Nano-
String nCounter system according to manufacturer’s instructions. A custom
nCounter codeset was used, which covers 500 genes that were selected for
their ability to monitor cell state, pluripotency, and differentiation (Table S6).
Because the nCounter system has been introduced only recently, no best
practices exist for normalizing the expression values. We tested several
different procedures and found that a combination of spike-in normalization
using positive controls and the VSN algorithm (Huber et al., 2002) produced
best results. Data analysis was performed with the R statistics package
(http://www.r-project.org/).Scorecard Calculation and Bioinformatics
The deviation scorecard is based on Tukey’s outlier filter (Tukey, 1977), denot-
ing all genes as putative outliers whose DNA methylation or gene expression
levels fall by more than 1.5 times the interquartile range outside of the center
quartiles. The lineage scorecard performs a parametric gene set enrichment
analysis on t scores obtained from a pairwise comparison between all
replicates of the cell line of interest and the reference of ES cell-derived EBs.
A more detailed description of the bioinformatic methods is available in Fig-
ure S4 and in the Extended Experimental Procedures.ACCESSION NUMBERS
Microarray data have been submitted to the Gene Expression Omnibus (GEO)
and are available under accession number GSE25970.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and seven tables and can be found with this article online at doi:10.
1016/j.cell.2010.12.032.ACKNOWLEDGMENTS
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